Market Overview

ScanSource's Q4 Earnings Preview

Share:

ScanSource (NASDAQ: SCSC) announces its next round of earnings this Tuesday, August 20. Here is Benzinga's everything-that-matters guide for the Q4 earnings announcement.

Earnings and Revenue

Wall Street expects EPS of 82 cents and sales around $999.63 million.

In the same quarter last year, ScanSource posted a profit of 77 cents on sales of $993.85 million. The Wall Street estimate would represent a 6.49% increase in the company's earnings. Revenue would be up 0.58% on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:

 

Quarter Q3 2019 Q2 2019 Q1 2019 Q4 2018
EPS Estimate 0.800 0.97 0.87 0.77
EPS Actual 0.770 0.99 0.89 0.77

Stock Performance

Over the last 52-week period, shares are down 25.98%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on ScanSource stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

ScanSource is scheduled to hold a conference call at 5:00 p.m. ET and it can be accessed here: https://edge.media-server.com/mmc/p/mymrnxnp

Posted-In: Earnings News

 

Related Articles (SCSC)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine

Earnings Preview: Nordson